CD274 and neoplasm: Single agent pembrolizumab (Keytruda), an anti-PD-1 monoclonal antibody, was FDA-approved for the treatment of advanced or recurrent oesophagogastric cancers in the third-line setting for tumours expressing PD-L1 (combined positive score (CPS) ≥1) [7].